As a result of huge costs and pricing pressures, many drug development players are now participating in public-private partnerships (PPP) to share the costs of drug development efforts. Read More ›
Hemp is not marijuana – let us start there. This is a critical distinction the Ohio legislature has learned through the lobbying efforts of our firm’s government relations subsidiary, CivicPoint LLC. CivicPoint has helped inform state lawmakers and advance a bill to legalize hemp and hemp-derived cannabidiol (CBD) products. Read More ›
West Virginia Governor Jim Justice, on March 26, 2019, signed House Bill 2538, which was intended to address banking issues that Treasurer John Perdue and the existing correspondent banks for the State of West Virginia previously raised with respect to the fees, penalties, and taxes authorized by the West Virginia Medical Cannabis Act. Read More ›
It’s no secret that the U.S. Department of Health and Human Services (HHS) recently launched a number of efforts aimed at enhancing transparency in the U.S. health care system. These efforts include better access to one’s own medical record information and various drug pricing disclosure initiatives. But... Read More ›
Ask the Blogger
Do you have a topic that you would like discussed in a future blog article? Please let us know. If you have a confidential question regarding a blog article, please feel free to contact the article's author directly, or let us know if you would like for someone to contact you directly.
Thomas D. Anthony is the former chair of FBT's Health Care Industry Team. He focuses on counseling health care entities on corporate transactions, regulatory compliance and joint ventures.